Intraoperative defibrillation threshold testing during implantable cardioverter-defibrillator insertion: do we really...

Area of Science:

• Cardiology
• Medical Devices
• Electrophysiology

Background:

• Implantable cardioverter-defibrillator (ICD) implantation traditionally includes defibrillation threshold (DFT) testing.
• Concerns regarding complications from DFT testing have led to questioning its necessity.
• The study aimed to evaluate the impact of DFT testing on ICD therapy efficacy.

Purpose of the Study:

• To assess whether defibrillation threshold (DFT) testing improves the efficacy of implantable cardioverter-defibrillator (ICD) therapy.
• To determine if routine DFT testing is essential for optimal ICD performance.
• To provide evidence for potential revisions in current ICD implantation guidelines.

Main Methods:

• A retrospective analysis of 122 patients undergoing ICD implantation between April 1996 and June 2008.
• Patients were divided into two groups: those who underwent DFT testing (n=42) and those who did not (n=80).
• Comparison of ventricular tachyarrhythmic episodes, antitachycardia pacing (ATP) success rates, and inappropriate shock deliveries between the groups over a 12-month follow-up period.

Main Results:

• No significant difference in the number of ventricular tachyarrhythmic episodes between the DFT and non-DFT groups (31.0% vs 37.5%, P = .472).
• Antitachycardia pacing (ATP) effectively terminated most episodes in both groups.
• Similar rates of inappropriate ATP interventions and shock deliveries were observed in both DFT and non-DFT groups.

Conclusions:

• Defibrillation threshold (DFT) testing does not appear to offer a significant efficacy advantage for implantable cardioverter-defibrillator (ICD) therapy at 1-year follow-up.
• The findings suggest that routine DFT testing may potentially be abandoned.
• Further prospective randomized trials and long-term follow-up are recommended to confirm these results and inform guideline revisions.